Table 3 Odds ratio of hypogonadism in childhood cancer survivors and testicular cancer patients with levels of inflammatory markers at baseline below or above the median of controls (n = 148)
Inflammatory marker | Eugonadal patients n = 113 (76%) | Hypogonadal patients n = 35 (24%) | OR (CI) Unadjusted | OR (CI) Adjusteda | ||
|---|---|---|---|---|---|---|
IL-6 | ||||||
 Low | 60 | (86) | 10 | (14) | ref. |  |
 High | 53 | (68) | 25 | (32) | 2.83 (1.25–6.43) | 2.73 (1.18–6.31) |
IL-8 | ||||||
 Low | 35 | (78) | 10 | (22) | ref. |  |
 High | 78 | (76) | 25 | (24) | 1.12 (0.49–2.59) | 1.23 (0.52–2.92) |
TNF-α | ||||||
 Low | 65 | (80) | 16 | (20) | ref. |  |
 High | 48 | (72) | 19 | (28) | 1.61 (0.75–3.45) | 1.77 (0.81–3.86) |
IL-10 | ||||||
 Low | 63 | (72) | 24 | (28) | ref. |  |
 High | 50 | (82) | 11 | (18) | 0.58 (0.26–1.29) | 0.60 (0.26–1.34 |
IL-6 and IL-10 | ||||||
 IL-6 low and/or IL-10 high | 91 | (82) | 20 | (18) | ref. |  |
 IL-6 High + IL-10 Low | 22 | (59) | 15 | (41) | 3.10 (1.37–7.01) | 2.89 (1.25–6.68) |